Epidiolex (generic name Cannabidiol or CBD for short) is an experimental medication granted orphan drug designation for use in treating children with Dravet syndrome, a rare and severe form of infantile-onset, genetic, drug-resistant epilepsy syndrome.
Epidiolex is an oral liquid formulation of a highly purified extract of CBD, a non-psychoactive molecule from the cannabis plant.
Results from the first 23 patients (average age, 10 years) show that after 3 months of therapy, 39% of patients had a greater than 50% reduction in seizures with a median reduction of 32%. Seizure freedom (no seizures for the last month of treatment) occurred in three of nine patients with syndrome and one of 14 patients with other forms of epilepsy.
Adverse effects were mostly mild or moderate and included somnolence, fatigue, weight loss or gain, diarrhea, and increased or decreased appetite.
Epidiolex is made by GW Pharmaceuticals.